AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 141 min read$RZLT

Rezolute, Inc. (RZLT) Completes Phase 3 upLIFT Enrollment; Topline Mid-Dec 2026

Rezolute, Inc. (RZLT) has completed patient enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism. Topline results are expected mid-December 2026. Earlier, 7 of the first 8 participants met the primary responder criterion, according to the company.

Original reporting
tradingview.com
Published Oct 14, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Rezolute, Inc. (RZLT) Completes Phase 3 upLIFT Enrollment; Topline Mid-Dec 2026 — source image
Source · tradingview.com
Decision brief

The 30-second read

$RZLTBullishMed
01

Why it matters

The enrollment milestone reduces near‑term execution risk and positions the company for a market‑moving data readout in December 2026.

02

Market read

A biotech milestone that could trigger significant price movement upon data release, relevant for specialty‑drug investors.

03

What to watch

Potential regulatory delays or enrollment quality issues not disclosed in the brief release.

Relevance 7/10Novelty 7/10Timing: mid‑December 2026 results

Background

Rezolute is a clinical‑stage biopharma focused on rare endocrine disorders. The upLIFT study evaluates ersodetug for tumor‑induced hyperinsulinism.

Company-level read

Ticker impact

$RZLTBullishHigh confidence
Context

Rezolute completed enrollment in its Phase 3 upLIFT study, with topline results expected mid‑December 2026.

Expected impact

potential upside as investors price in a positive readout of the Phase 3 trial

Evidence & confidence

Phase 3 enrollment is a material milestone for a biotech; market typically reacts strongly to the upcoming data release.

Market effects

Sector

May lift sentiment for the rare‑disease biotech sector as a peer reaches a pivotal trial stage.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If the trial fails to meet endpoints, the stock could tumble sharply, making the enrollment news a false positive.

Key entities

  • Company
    Rezolute, Inc.

    US‑listed biotech developing ersodetug.

Read at source← All news

StoryRezolute completes enrollment in Phase 3 upLIFT study, results due mid‑December 2026

Related articles

OCT 14
$RZLTMedAI 8/10

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare

SEC EDGAR 8-K2 min
OCT 14
$RZLTLowAI 8/10

Rezolute completes enrollment in phase 3 tumor study

Rezolute Inc. (RZLT) completed enrollment in its Phase 3 study of ersodetug for tumor hyperinsulinism, with 16 participants. Topline results are expected in mid-December 2026. The study's primary endpoint measures a 50% reduction in glucose infusion rate. Seven of the first eight participants met the responder criterion, and the treatment has been well-tolerated. Rezolute plans to continue its expanded access program.

investing.com2 min
OCT 6
$RZLTHighAI 8/10

H.C. Wainwright reiterates Buy on Rezolute stock, $10 target

H.C. Wainwright reiterated a Buy rating and $10 price target for Rezolute Inc. (RZLT) after FDA feedback on its ersodetug candidate. The stock trades at $4.33, with analysts citing regulatory developments and clinical trial progress. Rezolute plans to discuss both its congenital hyperinsulinism and tumor hyperinsulinism programs with the FDA, with upLIFT trial results expected by year-end 2026. The company has a strong balance sheet, according to InvestingPro Tips.

investing.com2 min
OCT 6
$RZLTMedAI 8/10

Citizens raises Rezolute stock price target on FDA feedback

Citizens raised its price target for Rezolute Inc. (RZLT) to $15.00 from $11.00, citing positive FDA feedback on its Phase 3 data for congenital hyperinsulinism. The stock, currently at $4.33, has a consensus 'Buy' rating with targets ranging from $6 to $14. Recent analyst updates and clinical trial progress also support the increased target.

investing.com2 min
OCT 5
$RZLTMedAI 8/10

Rezolute, Inc. (RZLT): On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-r

SEC EDGAR 8-K2 min